Why the study?
Does hANP infusion affect blood pressure, PAC, and hANP metabolism differently in patients with chronic renal failure compared to normal volunteers?
Does hANP infusion affect blood pressure, PAC, and hANP metabolism differently in patients with chronic renal failure compared to normal volunteers?
The kidney plays an important role in the degradation of hANP, as evidenced by prolonged half-life and reduced metabolic clearance in patients with chronic renal failure.
Answers are grounded in this paper and cite their sources.
Altered hANP clearance in CRF may require infusion caution; leaves open its hemodynamic impact in prospective studies.
Synthetic alpha-human atrial natriuretic peptide (hANP) was infused continuously at a rate of 80 ng/kg/min for 20 min into normal volunteers and patients with chronic renal failure (CRF) receiving hemodialysis. Blood pressure (BP) decreased significantly both in normals and in patients with CRF. The magnitude and the duration of the decrease, however, were greater in patients with CRF. The plasma aldosterone concentration (PAC) decreased significantly in normals and only minimally in patients with CRF. The half time (T1/2) of plasma hANP in patients with CRF (M +/- SE: 4.5 +/- 0.5 min) was longer than that in normals (1.8 +/- 0.2 min). Moreover, the metabolic clearance rate in patients with CRF (64 +/- 7 ml/kg/min) was less than in normals (150 +/- 20 ml/kg/min). Thus, the T1/2 in plasma of hANP in patients with CRF was noticeably longer than in a normal control group. These findings suggest that hANP suppresses PAC regardless of electrocyte imbalances and/or volume change induced by kidney dysfunction and that the kidney may be important in degrading hANP.
No takes yet. Share an insight, caveat, or question.
Takagi et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: